{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:19:38Z","timestamp":1768483178085,"version":"3.49.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National Cheng Kung University-Show Chwan Health Care System R&amp;D Project","award":["B-ER-108-096"],"award-info":[{"award-number":["B-ER-108-096"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>East Asians are reportedly at high risk of anticoagulant-related bleeding; therefore, some physicians prefer to prescribe low-dose direct oral anticoagulants (DOACs). Little is known about the therapeutic effectiveness and safety of off-label reduced-dose apixaban in East Asians with nonvalvular atrial fibrillation (AF). We aimed to investigate the effectiveness and safety of off-label reduced-dose apixaban in Taiwanese patients with nonvalvular AF.<\/jats:p>\n            <jats:p>This retrospective cohort study enrolled 1073 patients with nonvalvular AF who took apixaban between July 2014 and October 2018 from 4 medical centers in southern Taiwan. The primary outcomes included thromboembolic events (stroke\/transient ischemic attack or systemic embolism), major bleeding, and all-cause mortality.<\/jats:p>\n            <jats:p>Among all patients, 826 (77%) patients were classified as the \u201cper-label adequate-dose\u201d treatment group (i.e., consistent with the Food and Drug Administration label recommendations) while 247 (23%) patients were the \u201coff-label reduced-dose\u201d treatment group. The mean follow-up period was 17.5\u200a\u00b1\u200a13\u200amonths. The \u201coff-label reduced-dose\u201d group did not have a lower major bleeding rate than the \u201cper-label adequate-dose\u201d group (4.8% vs 3.8%, adjusted hazard ratio [HR] 1.20, 95% confidence interval [CI] 0.69\u20132.09), but had a nonsignificantly higher incidence of thromboembolic events (4.23% vs 3.05%, adjusted HR: 1.29, 95% CI: 0.71\u20132.34).<\/jats:p>\n            <jats:p>An off-label reduced-dose apixaban treatment strategy may not provide incremental benefits or safety for Taiwanese patients with nonvalvular AF.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026272","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T15:02:18Z","timestamp":1623423738000},"page":"e26272","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5935-0908","authenticated-orcid":false,"given":"I-Chih","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, Tainan Municipal Hospital"},{"name":"Department of Pharmacy, Chia Nan University of Pharmacy and Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ting","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, Chi-Mei Medical Center"},{"name":"Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Chao","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Lan","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, Tainan Municipal Hospital"},{"name":"Chang Gung University of Science and Technology, Chiayi Campus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syuan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Chi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hsien","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, Chi-Mei Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-Miin","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, Tainan Municipal Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Jen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, Tainan Municipal Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping-Yen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, National Cheng Kung University Hospital"},{"name":"Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Wen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, National Cheng Kung University Hospital"},{"name":"Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijcard.2014.11.182","article-title":"Nonvitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in asian patients with atrial fibrillation: time for a reappraisal","volume":"180","author":"Lip","year":"2015","journal-title":"Int J Cardiol"},{"key":"R2-20250504","first-page":"789","article-title":"Stroke prevention in atrial fibrillation: an Asian perspective","volume":"111","author":"Chiang","year":"2014","journal-title":"Thromb Haemost"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.thromres.2014.02.024","article-title":"Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan","volume":"133","author":"Chang","year":"2014","journal-title":"Thromb Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/eurheartj\/ehu028","article-title":"Early management of atrial fibrillation to prevent cardiovascular complications","volume":"35","author":"Nattel","year":"2014","journal-title":"Eur Heart J"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.clinthera.2008.09.010","article-title":"Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation-a nationwide descriptive study in taiwan","volume":"30","author":"Lin","year":"2008","journal-title":"Clin Ther"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","article-title":"Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation","volume":"50","author":"Shen","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1160\/TH11-04-0214","article-title":"Current antithrombotic treatment in East Asia: some perspectives on anticoagulation and antiplatelet therapy","volume":"107","author":"Ma","year":"2012","journal-title":"Thromb Haemost"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","article-title":"Nonvitamin K antagonist oral anticoagulants for stroke prevention in asian patients with nonvalvular atrial fibrillation: meta-analysis","volume":"46","author":"Wang","year":"2015","journal-title":"Stroke"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of nonvitamin K antagonist oral anticoagulants and adverse outcomes: the orbit-af ii registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","article-title":"Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in asians and nonasians with atrial fibrillation","volume":"44","author":"Hori","year":"2013","journal-title":"Stroke"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"j510","DOI":"10.1136\/bmj.j510","article-title":"Effectiveness and safety of reduced dose nonvitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"356","author":"Nielsen","year":"2017","journal-title":"BMJ"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.thromres.2018.07.024","article-title":"Appropriateness of nonvitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in israel: a population-based study","volume":"169","author":"Ellis","year":"2018","journal-title":"Thromb Res"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e008150","DOI":"10.1161\/JAHA.117.008150","article-title":"Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in asians with nonvalvular atrial fibrillation","volume":"7","author":"Chan","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijcard.2018.03.063","article-title":"The effectivenss and safety of low-dose rivaroxaban in Asians with nonvalvular atrial fibrillation","volume":"261","author":"Lee","year":"2018","journal-title":"Int J Cardiol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jacc.2016.06.062","article-title":"Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvula atrial fibrillation","volume":"68","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/STROKEAHA.118.023093","article-title":"Outcomes after use of standard- and low-dose nonvitamin K oral anticoagulants in Asian patients with atrial fibrillation","volume":"50","author":"Cho","year":"2019","journal-title":"Stroke"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e005362","DOI":"10.1161\/JAHA.116.005362","article-title":"Comparative effectiveness and safety of dabigatran and rivaroxaban in atrial fibrillation patients","volume":"6","author":"Lai","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan's national health insurance research database: past and future","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin Epidemiol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","article-title":"Independent predictors of stroke in patients with atrial fibrillation: a systematic review","volume":"69","year":"2007","journal-title":"Neurology"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1160\/TH08-11-0730","article-title":"Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients","volume":"102","author":"Palareti","year":"2009","journal-title":"Thromb Haemost"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.joa.2017.05.004","article-title":"2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation","volume":"33","author":"Chiang","year":"2017","journal-title":"J Arrhythm"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jfma.2016.10.005","article-title":"2016 guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of cardiology for the management of atrial fibrillation","volume":"115","author":"Chiang","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/STROKEAHA.114.007199","article-title":"Stroke and major bleeding risk in elderly patients aged 75\u200ayears with atrial fibrillation: the Loire Valley atrial fibrillation project","volume":"46","author":"Lip","year":"2015","journal-title":"Stroke"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Nonvitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"Yao","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/joim.12683","article-title":"Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study","volume":"283","author":"Staerk","year":"2018","journal-title":"J Intern Med"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"e0191722","DOI":"10.1371\/journal.pone.0191722","article-title":"Apixaban 5 and 2.5\u200amg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a propensity-score-matched approach","volume":"13","author":"Li","year":"2018","journal-title":"PLoS One"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3349\/ymj.2019.60.3.277","article-title":"Label adherence for nonvitamin K antagonist oral anticoagulants in a prospective cohort of asian patients with atrial fibrillation","volume":"60","author":"Lee","year":"2019","journal-title":"Yonsei Med J"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"e011112","DOI":"10.1161\/JAHA.118.011112","article-title":"Effectiveness and safety of nonvitamin K antagonist oral anticoagulant and warfarin in cirrhotic patients with nonvalvular atrial fibrillation","volume":"8","author":"Lee","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"e026645","DOI":"10.1136\/bmjopen-2018-026645","article-title":"Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of nonvitamin K antagonist oral anticoagulants: findings from the french healthcare databases, 2011-2016","volume":"9","author":"Maura","year":"2019","journal-title":"BMJ Open"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.amjmed.2019.01.025","article-title":"Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation","volume":"132","author":"Arbel","year":"2019","journal-title":"Am J Med"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","article-title":"Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (aristotle) trial","volume":"168","author":"Goto","year":"2014","journal-title":"Am Heart J"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/joa3.12184","article-title":"Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: a regulatory postmarketing surveillance, the STANDARD study","volume":"35","author":"Inoue","year":"2019","journal-title":"J Arrhythm"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/cpt.1952","article-title":"Stroke and bleeding risks in patients with atrial fibrillation treated with reduced apixaban dose: a real-life study","volume":"108","author":"Salameh","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jjcc.2019.07.007","article-title":"Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: a sub-analysis of the standard study","volume":"75","author":"Inoue","year":"2020","journal-title":"J Cardiol"},{"key":"R40-20250504","first-page":"pvab004","article-title":"Off-label underdosed apixaban use in Asian patients with nonvalvular atrial fibrillation","author":"Lee","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1161\/STROKEAHA.117.017549","article-title":"Real-world setting comparison of nonvitamin K antagonist oral anticoagulants versus vitamin K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis","volume":"48","author":"Ntaios","year":"2017","journal-title":"Stroke"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records","volume":"33","author":"Kim","year":"2018","journal-title":"J Korean Med Sci"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1161\/STROKEAHA.116.013540","article-title":"Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from engage AF-TIMI 48 (effective anticoagulation with factor XA next generation in atrial fibrillation-thrombolysis in myocardial infarction 48)","volume":"47","author":"Rost","year":"2016","journal-title":"Stroke"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.arr.2018.10.006","article-title":"Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation","volume":"49","author":"Katoa","year":"2019","journal-title":"Ageing Res Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:35:56Z","timestamp":1746336956000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026272"}},"subtitle":["A retrospective, observational study"],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":44,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026272","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]},"assertion":[{"value":"2021-02-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}